LDC and Qurient will collaborate on anti-cancer compound

3 June 2015

German translational drug discovery organization The Lead Discovery Center GmbH (LDC) and Qurient, a spin-off biotech company from Institute Pasteur Korea (IPK) have signed a licence deal for a novel anti-cancer compound.

The deal provides Qurient with exclusive worldwide rights to a series of highly-selective CDK7 inhibitors discovered at the LDC for the treatment of cancer, inflammation and viral infections. The aim is to advance the approach from the validated lead stage into clinical development. Upon successful proof-of-concept in humans they will jointly identify a suitable partner for follow-on licensing. Under the terms of the agreement LDC will receive an upfront payment and milestone payments upon the achievement of specific development events. In addition, Qurient will fund the future development activities of the collaborative program.

Second deal

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK